Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein
21 déc. 2021 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has closed on...
Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein
21 sept. 2021 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has entered...
Galectin Therapeutics Strengthens Leadership Team with Strategic Hires to Advance Programs in Cancer Immunotherapy and NASH Cirrhosis
30 août 2021 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has...
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2021, and Provides Business Update
16 août 2021 09h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...
Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck Cancer
09 juil. 2021 08h00 HE
|
Galectin Therapeutics Inc.
Belapectin and KEYTRUDA® combination immunotherapy in patients with treatment-refractory and progressive diseases shows a cancer control rate of 56% in melanoma and of 40% in head and neck...
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business Update
17 mai 2021 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 17, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...
World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin Therapeutics as Special Consultant to Accelerate and Enhance Development of Company’s Galectin-3 Inhibitor, Belapectin
19 avr. 2021 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 19, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has engaged Dr....
Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy
13 avr. 2021 19h01 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 13, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper...
Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis Study
06 avr. 2021 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 06, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of...
Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update
31 mars 2021 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 31, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...